Session

Innovations in staging of prostate cancer

Poster Session 66

  • Location:
    Room London, North Hall (Level 1)
  • Chairs:
     N. Fossati, Milan (IT)
     M. Lardas, Nea Smirni-Athens (GR)
     J. Hugosson, Göteborg (SE)
  • Aims and objectives of this session

    This session will examine Innovations in prostate cancer staging, prognostic groups and lymph node identification.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
869
11C-choline versus 68Ga-PSMA PET/CT scan for the detection of nodal recurrence from prostate cancer: Results from a large, multi-institutional salvage lymph node dissection series

By: Fossati N.1, Briganti A.1, Gandaglia G.1, Suardi N.1, Colicchia M.2, Karnes J.2, Haidl F.3, Porres D.3, Pfister D.3, Heidenreich A.3, Herlemann A.4, Gratzke C.4, Stief C.4, Battaglia A.5, Everaerts W.5, Joniau S.5, Van Poppel H.5, Aksenov A.6, Osmonov D.K.6, Jünemann K.P.6, Abreu A.D.L.8, Almeida F.8, Fay C.7, Gill I.7, Mottrie A.M.9, Montorsi F.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, 3University of Cologne, Dept. of Urology, Cologne, Germany, 4Ludwig-Maximilians-University Munich,, Dept. of Urology, Munich, Germany, 5University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, 6University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Campus Kiel, Germany, 7Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern Cal, USC Institute of Urology, Los Angeles, California, United States of America, 8Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, 9OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium

870
Introducing PSMA-Bone-PET-Index for quantitative assessment of osseous tumor burden in prostate cancer

By: Bieth M.2, Krönke M.2, Maurer T.1, Tauber R.1, Dahlbender M.1, Retz M.1, Gschwend J.1, Nekolla S.2, Menze B.2, Eiber M.2, Schwaiger M.2

Institutes: 1Klinikum rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, 2Klinikum rechts der Isar der Technischen Universität München, Dept. of Nuclear Medicine, Munich, Germany

871
Performance of 111In-PSMA-ligand radioguided surgery for identification of lymph node metastases: Correlation of tracer uptake and histopathology based on 310 single lymph nodes separated from lymphadenectomies in prostate cancer patients

By: Schaal K.1, Mix M.2, Stoykow C.2, Bartholomä M.2, Drendel V.3, Mäcke H.2, Gourni E.2, Wetterauer U.1, Schultze-Seemann W.1, Meyer P.T.2, Jilg C.A.1

Institutes: 1Medical Center, University of Freiburg, Faculty of Medicine, Dept. of Urology, Freiburg, Germany, 2Medical Center, University of Freiburg, Faculty of Medicine, Dept. of Nuclear Medicine, Freiburg, Germany, 3Medical Center, University of Freiburg, Faculty of Medicine, Institute for Pathology, Freiburg, Germany

872
Prospective comparison of molecular and histopathologic detection of lymph node metastases in prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection: Prediction of biochemical recurrence

By: Heck M.1, Retz M.1, Bandur M.1, Souchay M.1, Vitzthum E.1, Weirich G.2, Schuster T.3, Autenrieth M.1, Kübler H.1, Maurer T.1, Thalgott M.1, Herkommer K.1, Gschwend J.1, Nawroth R.1

Institutes: 1Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Urology, Munich, Germany, 2Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Pathology, Munich, Germany, 3McGill University, Dept. of Family Medicine, Montreal, Canada

873
Indication to pelvic lymph nodes dissection for prostate cancer: The role of prostate multiparametric MRI if the risk of lymph nodes invasion according to Briganti updated nomogram is <5%

By: Porpiglia F.1, Manfredi M.1, Mele F.1, Bertolo R.1, Cattaneo G.1, Passera R.2, De Pascale A.3, Gned D.3, Veltri A.3, Regge D.4, Russo F.4, Cirillo S.5, Fiori C.1

Institutes: 1San Luigi Hospital, Dept. of Urology, Turin, Italy, 2San Giovanni Battista Hospital, Dept. of Nuclear Medicine, Turin, Italy, 3San Luigi Hospital, Dept. of Radiology, Turin, Italy, 4IRCC Candiolo, Dept. of Radiology, Turin, Italy, 5Mauriziano Hospital, Dept. of Radiology, Turin, Italy

874
Can we modulate the extent of nodal dissection according to the preoperative risk of lymph node invasion in prostate cancer patients undergoing radical prostatectomy?

By: Gandaglia G., Zaffuto E., Dell’Oglio P., Fossati N., Scattoni V., Bianchi M., Gallina A., Capitanio U., Gaboardi F., Montorsi F., Briganti A.

Institutes: Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy

875
Characteristics of MRI staging using PI-RADS version 2 and its predictive performance for biochemical recurrence after radical prostatectomy compared to PI-RADS version 1

By: Matsuoka Y.1, Ishioka J.1, Tanaka H.2, Kimura T.2, Inoue M.1, Ito M.1, Kijima T.1, Yoshida S.1, Yokoyama M.1, Saito K.1, Kihara K.1, Fujii Y.1

Institutes: 1Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, 2Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan

880
External validation of a new clinical prognostic grouping to improve prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer

By: Gnanapragasam V.1, Bratt O.2, Stattin P.3, Lee L.5, Huang H.5, Muir K.4, Lophatananon A.4

Institutes: 1University of Cambridge, Academic Urology Group, Dept. of Surgery, Cambridge, United Kingdom, 2Addenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom, 3Umea University, Dept. of Surgical and Perioperative Science, Umea, Sweden, 4Institute of Population Health, Manchester, United Kingdom, 5Singapore General Hospital, Dept. of Urology, Singapore, Singapore

876
Ability of a new clinical prognostic grouping to better predict disease mortality after treatment in primary non-metastatic prostate cancer

By: Gnanapragasam V.J.1, Lophatananon A.4, Muir K.4, Stattin P.3, Bratt O.2

Institutes: 1University of Cambridge, Academic Urology Group, Dept. of Surgery, Cambridge, United Kingdom, 2Addenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom, 3Umea University, Dept. of Surgical and Perioperative Science, Umea, Sweden, 4University of Manchester, Institute of Population Health, Manchester, United Kingdom

877
Expression of tumor progression-associated genes in circulating tumor cells of patients with different stages of prostate cancer

By: Bier S.1, Hennenlotter J.1, Beger G.1, Pavlenco L.1, Feniuk N.2, Hauch S.3, Rausch S.1, Stenzl A.1, Todenhöfer T.1

Institutes: 1Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, 2Qiagen, Dept. of Reasearch and Development, Hilden, Germany, 3Qiagen, Dept. of Research and Development, Hilden, Germany

* 878
Current and projected prevalence of prostate cancer according to risk-categories. A nation-wide and population-based study

By: Folkvaljon Y.1, Garmo H.2, Ventimiglia E.3, Holmberg L.2, Stattin P.4

Institutes: 1Regional Cancer Centre Uppsala/örebro, Dept. of Surgical Sciences, Uppsala, Sweden, 2King’s College London, Faculty of Life Sciences and Medicine, Division of Cancer Studies, London, United Kingdom, 3IRCCS Ospedale San Raffaele, Division of Experimental Oncology/Unit of Urology; URI, Milan, Italy, 4Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

879
Are the results of the ProtecT trial applicable to contemporary prostate cancer patients treated at two high-volume European Institutions?

By: Gandaglia G.1, Zaffuto E.1, Fossati N.1, Dell’Oglio P.1, Cucchiara V.1, Pompe R.2, Suardi N.1, Rigatti P.3, Graefen M.2, Montorsi F.1, Tilki D.2, Briganti A.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, 3Advanced Urotechnology Center, Scientific Institute “Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy

881
Do more granular Gleason categorizations lead to better prognostic accuracy over time?

By: Fankhauser C.1, Wilson K.4, Rider J.5, Penney K.4, Peisch S.6, Fiorentino M.7, Kantoff P.8, Moch H.2, Mucci L.4, Gerke T.3

Institutes: 1University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, 2University Hospital Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland, 3Moffitt Cancer Center, Dept. of Epidemiology, Tampa, United States of America, 4Harvard T.H. Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America, 5Boston University, Dept. of Epidemiology, Boston, United States of America, 6Brigham and Women’s Hospital/Harvard Medical School, Channing Division of Network Medicine, Dept. of Medicine, Boston, United States of America, 7S. Orsola-Malpighi Hospital, Addarii Institute, Dept. of Pathology, Bologna, Italy, 8Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America

New methods in staging of prostate cancer
 M. Lardas, Nea Smirni-Athens (GR)